NEUN News 0.0080 Neurogenesis Inc (NEUN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Neurogenesis Inc (NEUN) 0.0080 $NEUN

NeuroGenesis Dietary Supplements Are Covered by Issued Patents
Marketwire - Thu Nov 21, 7:30AM CST
NeuroGenesis, Inc. (PINKSHEETS: NEUN) has been marketing and selling a variety of patented supplements into the large supplement marketplace for over 25 years. The Company's products range from Neu BeCalm'd (beneficial for relief of stress; improves mental focus and concentration; helps establish normal sleep patterns) to NeuRelieve (supplements to replenish neurotransmitters depleted by benzodiazepine), NeuRecover (supplements to replenish neurotransmitters depleted by alcohol), NeuReplenish (supplements to replenish neurotransmitters depleted by use of chemical stimulants) and NeuSlim (provides nutritional support for healthy weight loss and maintenance). With over 30 years of scientific research and clinical studies and use in over 1,700 US hospitals and drug rehab centers.

NeuroGenesis Dietary Supplement, NeuSlim, Sells Into a $11.5 Billion US Market
Marketwire - Mon Oct 28, 7:31AM CDT
NeuroGenesis, Inc. (PINKSHEETS: NEUN) -- In addition to our Neu BeCalm'd supplement, NeuroGenesis offers NeuSlim to the dietary supplement market, which aids in the reduction of cravings (or urges) for simple carbohydrates such as sugar and has been reported to reduce excessive appetite in general and assist in healthy moderation of nutritional needs. We believe we have a unique product that addresses a $11.5 Billion market (figures for 2012) which is forecasted to reach $15.5 billion by 2017.

NeuroGenesis' Neu BeCalm'd Supplement Aids in Managing PTSD for the Returning Military
Marketwire - Mon Oct 21, 8:02AM CDT
NeuroGenesis, Inc. (PINKSHEETS: NEUN) -- With numerous suicides monthly by returning veterans suffering from PTSD as reported in the Galveston Daily News and talked about on national talk shows like the Rush Limbaugh show, one company may have the answer.

NeuroGenesis Supplements Address a Host of Substance Abuse Issues
Marketwire - Fri Oct 18, 8:00AM CDT
NeuroGenesis, Inc. (PINKSHEETS: NEUN) -- Nutritional Supplements are formulations of vitamins, minerals and amino acids that are designed to assist the brain in balancing and rebuilding neurotransmitters to achieve and maintain a chemical balance. This chemical rebuilding process of neurotransmitters has brought relief and freedom to thousands. The Company has been publicly traded for over twenty years and also has four different supplements that address the negative effects of Alcohol (NeuRecover), Anti Anxiety Drugs (NeuRelieve), Chemical Stimulants (NeuReplenish), and also for prolonged use of prescription pain pills and opiate drugs (The Combo). The supplements come in bottles of 90 capsules. The Company is excited to be of help to anyone that is going through these above problems.

Photo Release -- Leading Brands, Inc. Announces the Launch of "Neurogenesis(TM) HAPPY WATER(TM)"
GlobeNewswire - Thu Feb 21, 7:30AM CST
Leading Brands, Inc. (Nasdaq:LBIX), North America's only fully integrated healthy branded beverage company, is pleased to announce the Canada-wide launch of its new "Naturally Beneficial" brand: Neurogenesis(TM) HAPPY WATER(TM). This follows an eight month test marketing program in Vancouver.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 55

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 49

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 618

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 52

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating the Legacy of the Kashi Fair: A Cultural Journey

Updated Category News Views 387

The Kashi Fair: A Living Tribute to the Silk Road The Kashi Fair, also known as the Kashi-Central and South Asia Commodity Fair, has become an essential trade event, connecting cultures and economies while celebrating the essence of the historic Silk Road. For Pakistani businessman Muhammad Abbas, the Managing Director of Pakistan Northern Gems, this annual event in Kashi...

Continue Reading
Global Forum Focuses on Sustainable Future and Cooperation

Updated Category News Views 260

Global Leaders Gather to Discuss a Sustainable Future Under the theme "Collective Action for One Future", a significant forum took place in a vibrant city, bringing together over 130 leaders from various nations. This event marked the ninth edition of an esteemed international gathering focused on transformative issues affecting the worldwide landscape. For the first...

Continue Reading
Blue Onion Secures $10 Million to Enhance Financial Data Management

Updated Category News Views 294

Blue Onion Secures $10 Million Series A Funding In a significant advancement for financial data management, Blue Onion has successfully secured $10 million in a Series A funding round, led by Viola FinTech. This strategic investment aims to broaden Blue Onion's capabilities in delivering accurate and fully reconciled transaction-level data that CFOs can trust. With this...

Continue Reading
Lilly's Retatrutide Outshines Ozempic in Key Diabetes Trial

Updated Category News Views 120

Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...

Continue Reading
Investing in Houlihan Lokey: A Decade of Growth Insights

Updated Category News Views 176

Understanding the Investment Journey with Houlihan Lokey Houlihan Lokey (NYSE: HLI) has demonstrated remarkable performance over the past decade. This investment bank has outshined market averages, yielding an impressive annualized return of 22.61%. As of now, Houlihan Lokey boasts a significant market capitalization of $12.57 billion, showcasing its robust standing in...

Continue Reading